Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity

Blood

Volumn 114, Issue 18, 2009, Pages 3938-3946

  Meems, Henriët ^a,b   Meijer, Alexander B ^a,c   Cullinan, David B ^d   Mertens, Koen ^a,b,c   Gilbert, Gary E ^d  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8C; MUTANT PROTEIN; BLOOD CLOTTING FACTOR 8; EPITOPE; LYSINE; MONOCLONAL ANTIBODY; PHENYLALANINE;

ARTICLE; BINDING AFFINITY; HUMAN; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN MOTIF; THROMBOCYTE ACTIVATION; AMINO ACID SUBSTITUTION; ARTIFICIAL MEMBRANE; CELL MEMBRANE; CHEMISTRY; COENZYME; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

AMINO ACID MOTIFS; AMINO ACID SUBSTITUTION; ANTIBODIES; ANTIBODIES, MONOCLONAL; CELL MEMBRANE; COENZYMES; EPITOPES; FACTOR VIII; HUMANS; LYSINE; MEMBRANES, ARTIFICIAL; MUTATION; PHENYLALANINE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 70449709337     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-197707     Document Type: Article

References (45)

1. Gilbert GE, Furie BC, Furie B. Binding of human factor VIII to phospholipid vesicles. J Biol Chem. 1990;265:815-822.
2. Gilbert GE, Drinkwater D. Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine. Biochemistry. 1993;32:9577-9585.
3. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 1990;76:1-16.
4. Mertens K, Cupers R, Van Wijngaarden A, Bertina RM. Binding of human blood-coagulation factors IXa and X to phospholipid membranes. Biochem J. 1984;223:599-605.
5. Esmon CT, Owen WG, Jackson CM. The conversion of prothrombin to thrombin: V. The activation of prothrombin by factor Xa in the presence of phospholipid. J Biol Chem. 1974;249(24):7798-7807.
6. Vehar G, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984;312:337.
7. Church WR, Jernigan RL, Toole J, et al. Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins. Proc Natl Acad Sci U S A. 1984;81:6934-6937.
8. Shao C, Novakovic VA, Head JF, Seaton BA, Gilbert GE. Crystal structure of lactadherin C2 domain at 1.7 angstrom resolution with mutational and computational analyses of its membrane-binding motif. J Biol Chem. 2007;283(11):7230-7241.
9. Stubbs J, Lekutis C, Singer K, et al. cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidemal growth factor-like domains linked to factor VIII-like sequences. Proc Natl Acad Sci U S A. 1990;87:8417-8421.
10. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature. 1984;312:326-330.
11. Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem. 1994;269:20522-20527.
12. Kolkman JA, Lenting PJ, Mertens K. Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are factor VIII-interactive sites involved in stimulation of enzyme activity. Biochem J. 1999;339:217-221.
13. Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA, Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem. 1996;271(4):1935-1940.
14. Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248-2312 which overlap a phopholipid binding site. Blood. 1995;86:1811-1819.
15. Ahmad SS, Walsh PN. Role of the C2 domain of factor VIIIa in the assembly of factor-X activating complex on the platelet membrane. Biochemistry. 2005;44(42):13858-13865.
16. Peng W, Quinn-Allen MA, Kim SW, Alexander KA, Kane WH. Trp2063 and trp2064 in the factor Va C2 domain are required for high-affinity binding to phospholipid membranes but not for assembly of the prothrombinase complex. Biochemistry. 2004;43(14):4385-4393.
17. Peng W, Quinn-Allen MA, Kane WH. Mutation of hydrophobic residues in the factor Va C1 and C2 domains blocks membrane-dependent prothrombin activation. J Thromb Haemost. 2005;3(2):351-354.
18. Saleh M, Peng W, Quinn-Allen MA, et al. The factor V C1 domain is involved in membrane binding: identification of functionally important amino acid residues within the C1 domain of factor V using alanine scanning mutagenesis. Thromb Haemost. 2004;91(1):16-27.
19. Hoyer LW. Hemophilia A. N Engl J Med. 1994; 330(1):38-47.
20. Ljung RC. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol. 1995;94[suppl 1]:49-52.
21. Spiegel PC Jr, Jacquemin M, Saint-Remy JM, Stoddard BL, Pratt KP. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood. 2001;98(1):13-19.
22. van den Brink EN, Turenhout EA, Bovenschen N, et al. Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VIII. Blood. 2001;97(4):966-972.
23. Mertens K, Gestel D, van Stempvoort G, Limburg V, Moret EE, Meijer AB. Somatic mutations in factor VIII inhibitors determine their factor VIII binding and inhibitory properties [abstract]. Blood. 2007;110(suppl):abstract 1762.
24. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. Three-dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood. 2002;99(4):1215-1223.
25. Ngo JC, Huang M, Roth DA, Furie BC, Furie B. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure. 2008;16(4):597-606.
26. Shen BW, Spiegel PC, Chang CH, et al. The tertiary structure and domain organization of coagulation factor VIII. Blood. 2008;111:1240-1247.
27. Hsu TC, Pratt KP, Thompson AR. The factor VIII C1 domain contributes to platelet binding. Blood. 2008;111(1):200-208.
28. Takeshima K, Smith C, Tait J, Fujikawa K. The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost. 2003;89(5):788-794.
29. van Helden PM, van den Berg HM, Gouw SC, et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol. 2008;142(4):644-652.
30. van den Biggelaar M, Bierings R, Storm G, Voorberg J, Mertens K. Requirements for cellular co-trafficking of factor VIII and von Willebrand factor to Weibel-Palade bodies. J Thromb Haemost. 2007;5(11):2235-2242.
31. Fribourg C, Meijer AB, Mertens K. The interface between the EGF2 domain and the protease domain in blood coagulation factor IX contributes to factor VIII binding and factor X activation. Biochemistry. 2006;45(35):10777-10785.
32. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
33. Donath MS, Lenting PJ, van Mourik JA, Mertens K. The role of cleavage of the light chain at positions Arg1689 or Arg1721 in subunit interaction and activation of human blood coagulation factor VIII. J Biol Chem. 1995;270(8):3648-3655.
34. Gilbert GE, Drinkwater D, Barter S, Clouse SB. Specificity of phosphatidylserine-containing membrane binding sites for factor VIII: studies with model membranes supported by glass microspheres (Lipospheres). J Biol Chem. 1992;267:15861-15868.
35. Barrow DA, Lentz BR. Large vesicle contamination in small, unilamellar vesicles. Biochim Biophys Acta. 1980;597(1):92-99.
36. Phillips JE, Lord ST, Gilbert GE. Fibrin stimulates platelets to increase factor VIIIa binding site expression. J Thromb Haemost. 2004;2(10):1806-1815.
37. Jacquemin MG, Desqueper BG, Benhida A, et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood. 1998;92(2):496-506.
38. Shi J, Pipe SW, Rasmussen JT, Heegaard CW, Gilbert GE. Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure. J Thromb Haemost. 2008;6(7):1167-1174.
39. Gilbert GE, Novakovic VA, Cullinan DB, Jacquemin M. Inhibitor antibody LE2E9 against factor VIII C1 domain inhibits phospholipid binding and alters factor Xase enzyme complex formation. J Thromb Haemost. 2007;5[suppl]:P-S-O42.
40. Gilbert GE, Kaufman RJ, Arena AA, Miao H, Pipe SW. Four hydrophobic amino acids in the factor VIII C2 domain are constituents of the membrane-binding and von Willebrand factor-binding motif. J Biol Chem. 2002;277(8):6374-6381.
41. Novakovic VA, Baleja JD, Gilbert GE. The factor VIII C2 domain shows stereospecificity for phosphatidyl-L-serine and increases factor IXa activity. Blood. 2008;112(11):Abstract 3090.
42. Brinkman HJ, Mertens K, van Mourik JA. Phospholipid-binding domain of factor VIII is involved in endothelial cell-mediated activation of factor X by factor IXa. Arterioscler Thromb Vasc Biol. 2002;22(3):511-516.
43. Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem. 1996;271:27424-27431.
44. Bardelle C, Furie B, Furie BC, Gilbert GE. Kinetic studies of factor VIII binding to phospholipid membranes indicate a complex binding process. J Biol Chem. 1993;268:8815-8824.
45. Lin Y, Chang L, Solovey A, Healey JF, Lollar P, Hebbel RP. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood. 2002;99(2):457-462.